Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tominersen in Prodromal and Early Manifest Huntington's Disease
NCT05686551Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2023
- Primary completion
- May 2026
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 15
01
Overview
A Phase 2 trial of tominersen in Huntington's disease (HD), sponsored by Roche. Started Feb 2023; status: active, not recruiting.
02
Drugs
tominersen
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT05686551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686551.